Biography

Dr. Chuanxi Tang is an Associate Professor and Master’s Supervisor at Xuzhou Medical University. He received his PhD in Neurobiology from Xuzhou Medical University in 2020. From 2019 to 2020, he was a visiting scholar at the College of Medicine of Drexel University, USA, where he conducted research on stem cell transplantation and neural repair following spinal cord injury.

Dr. Tang’s current research focuses primarily on the mechanisms underlying Parkinson’s disease-associated cognitive impairment. Using lipid metabolites as mediators, his research investigates their roles in dopaminergic axonal degeneration, pathological protein aggregation, neuronal death, neurotransmitter imbalance, and neural network degeneration. His research also involves the screening of small-molecule compounds and the exploration of their neuroprotective mechanisms in neurodegenerative diseases.

Education

Xuzhou Medical University, Neurobiology, 09/2017 – 12/2020, PhD

Xuzhou Medical University, Neurobiology, 09/2014 – 06/2017, M.S.

Xuzhou Medical University, Rehabilitation Therapy, 09/2010 – 06/2014, B.A.

Publications:

1. Yan, Y., Gao, L., Qiang, X., Qiu, Y., Shen, Y., Mu, C., Tang, C. (2026). Regulation of short-term declarative memory by selective activation of the locus coeruleus-retrosplenial cortex dopaminergic pathway and its pathological alterations in Parkinson's disease. Progress in neuro-psychopharmacology & biological psychiatry, 146, 111680.

2. Mu C, Zhou Z, Li J, Su M, Xue K, Zhang J, Shi S, Li Y, Yao X, Wang M, Zhang W, Wang Z, Zhu J, Fang S, Wang W, Tang C, Qin X. GDNF signaling modulation by Akkermansia muciniphila ameliorates constipation-depression comorbidity in Parkinson's disease. NPJ Parkinsons Dis. 2025 Nov 28;11(1):342.

3. Mu C, Shao K, Su M, Guo Y, Qiu Y, Sun R, Sun S, Sun Y, Liu C, Wang W, Qin X, Tang C. Lysophosphatidylcholine promoting α-Synuclein aggregation in Parkinson's disease: disrupting GCase glycosylation and lysosomal α-Synuclein degradation. NPJ Parkinsons Dis. 2025 Mar 15;11(1):47.

4. Wang W, Shi S, Su M, Li Y, Yao X, Jiang J, Yao W, Qin X, Wang Z, Tang C. Akkermansia muciniphila Akk11 Supplementation Attenuates MPTP-Induced Neurodegeneration by Inhibiting Microglial NLRP3 Inflammasome. Probiotics Antimicrob Proteins. 2025 Mar 6.

5. Liu Y, Chen R, Mu C, Diao J, Guo Y, Yao X, Shi S, Wang M, Zhang Z, Qin X, Tang C. Enhanced Microglial Engulfment of Dopaminergic Synapses Induces Parkinson's Disease-Related Executive Dysfunction in an Acute LPC Infusion Targeting the mPFC. Aging Cell. 2025 Feb 15:e70003.

6. Kambey PA, Wu J, Liu W, Su M, Buberwa W, Tang C. Targeting serum response factor (SRF) deactivates ΔFosB and mitigates Levodopa-induced dyskinesia in a mouse model of Parkinson's disease. Gene Ther. 2024 Nov;31(11-12):614-624. doi: 10.1038/s41434-024-00492-8. Epub 2024 Oct 9.

7. Liu Y, Zhou X, Xue K, Sun R, Tang Y, Tang C. Reviving: restoring depression-like behaviour through glial cell-derived neurotrophic factor treatment in the medial prefrontal cortex. J Psychiatry Neurosci. 2024 Feb 1;49(1):E23-E34. doi: 10.1503/jpn.230079. PMID: 38302136; PMCID: PMC10843345.

8. Tang C, Sun R, Xue K, Wang M, Liang S, Kambey PA, Shi M, Wu C, Chen G, Gao D. Distinct serum GDNF coupling with brain structural and functional changes underlies cognitive status in Parkinson's disease. CNS Neurosci Ther. 2023 Sep 17.

9. Zhou Z, Yan Y, Gu H, Sun R, Liao Z, Xue K, Tang C. Dopamine in the prefrontal cortex plays multiple roles in the executive function of patients with Parkinson's disease. Neural Regen Res. 2024 Aug 1;19(8):1759-1767.

10. Tang CX, Chen J, Shao KQ, Liu YH, Zhou XY, Ma CC, Liu MT, Shi MY, Kambey PA, Wang W, Ayanlaja AA, Liu YF, Xu W, Chen G, Wu J, Li X, Gao DS (2023) Blunt dopamine transmission due to decreased GDNF in the PFC evokes cognitive impairment in Parkinson’s disease. Neural Regen Res 18(5):1107-1117.